Finland · Delayed Price · Currency is EUR Nanoform Finland Oyj Earnings Call Transcripts
Fiscal Year 2025
-
Record revenue and EBITDA were achieved in 2025, supported by new IP, commercial deals, and expansion into Asia. Cash burn is targeted below €10M for 2026, with strong cash reserves and potential milestone upside. Biologics and subcutaneous delivery represent key growth areas.
-
Secured a commercial GMP manufacturing license, expanded product pipeline, and improved cash burn rate to EUR 3.9 million in Q3 2025. Strong cash position and new partnerships support growth, with targets for 2026 cash burn below EUR 10 million.
-
Q2 2025 saw 23% revenue growth, improved cash flow, and a 98% gross margin, with strong progress in both small molecule and biologics platforms. Key milestones include the first license agreement for nanoenzalutamide, ongoing pivotal studies, and expanded global partnerships.
-
Strong Q1 performance with record project growth, reduced cash burn, and expanded pharma partnerships. Key product kernels advanced, including nanoenzalutamide, with pivotal trial preparations and new patent granted. Cash position remains robust, supporting continued innovation.
Fiscal Year 2024
-
Record project signings and revenue growth of 8% year-over-year highlight strong commercial momentum, with pivotal studies and commercial deals for key product kernels expected soon. Manufacturing and clinical milestones remain on track, and cost discipline is emphasized.
-
Q3 saw record non-GMP project signings, a return to revenue growth, and strong commercial traction with major pharma partners. Gross margin is set to exceed 90% due to operational efficiencies, and several deals on key product candidates are expected in coming quarters.
-
Nanoform reported sequential revenue growth in Q2 2024, improved cash flow, and strong liquidity. Significant commercial traction was seen, especially in biologics after the Takeda collaboration, with record project signings expected in Q3.